MARKET

CLBS

CLBS

Caladrius
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.710
+0.049
+2.97%
Closed 16:00 04/02 EDT
OPEN
1.663
PREV CLOSE
1.661
HIGH
1.795
LOW
1.663
VOLUME
3.95K
TURNOVER
--
52 WEEK HIGH
3.683
52 WEEK LOW
1.050
MARKET CAP
18.19M
P/E (TTM)
-0.9124
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CLBS stock price target is 10.50 with a high estimate of 18.50 and a low estimate of 6.00.

EPS

CLBS News

More
  • Edited Transcript of CLBS earnings conference call or presentation 5-Mar-20 9:30pm GMT
  • Thomson Reuters StreetEvents · 03/25 05:47
  • Memgen Appoints Gregory Brown as Chief Executive Officer
  • Newsfile · 03/17 12:00
  • The Truth About Market Timing - March 06, 2020
  • Zacks · 03/06 14:22
  • Caladrius Biosciences EPS misses by $0.03
  • seekingalpha · 03/06 02:07

Industry

Biotechnology & Medical Research
+3.33%
Pharmaceuticals & Medical Research
+2.80%

Hot Stocks

Symbol
Price
%Change

About CLBS

Caladrius Biosciences, Inc. is a late-stage therapeutics development biopharmaceutical company that provides cell therapies for cardiovascular and autoimmune diseases. The Company’s product candidates include three developmental treatments for cardiovascular diseases based on its classification determinant34+ (CD34+) cell therapy platform. Its CLBS12 product candidate is a recipient of a SAKIGAKE designation in Japan and advanced therapy medicinal product classification (ATMP) in Europe. Its CLBS16 product candidate is being developed for the treatment of coronary microvascular dysfunction (CMD). Its CLBS14 product candidate is a phase III ready clinical program in no option refractory disabling angina. CLBS14 is a recipient of a regenerative medicine advanced therapy (RMAT) designation in the United States. It also has an autoimmune product candidate, CLBS03, which is being developed for the treatment of type I diabetes.
More

Webull offers kinds of Caladrius Biosciences Inc stock information, including NASDAQ:CLBS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLBS stock news, and many more online research tools to help you make informed decisions.